Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Prednisone for KHE with KMP
NCT04409691Phase 1Unknown
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nab-sirolimus in kaposiform hemangioendothelioma (KHE) and Kasabach-Merritt phenomenon (KMS) (2 arms). Primary endpoint: response to treatment at 6 months. Status: unknown.
02
Drugs
nab-sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)Kasabach-Merritt phenomenon (KMS)
Beyond the preview
Go deeper on NCT04409691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409691.